Melanoma Diagnostic Developer MELA Sciences Hosts Clinical Advisory Meeting & Exhibits Four Clinical Posters at Winter Clinical

  Melanoma Diagnostic Developer MELA Sciences Hosts Clinical Advisory Meeting
  & Exhibits Four Clinical Posters at Winter Clinical Dermatology Conference -
  January 17 - 22

Business Wire

KONA COAST, Hawaii & IRVINGTON, N.Y. -- January 16, 2014

MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind^®, an FDA-approved
optical diagnostic device that assists dermatologists in the diagnosis of
melanoma, will host its third company-sponsored Clinical Advisory meeting for
select dermatologists and key opinion leaders in melanoma and provide recent
clinical findings at the Winter Clinical Dermatology Conference being held
January 17-22 at the Fairmont Orchid Hotel, Kona Coast, Hawaii.

MELA Sciences’ Clinical Advisory meeting, for current and prospective
MelaFind^® users and thought leaders, will discuss technical advancements for
the MelaFind^® device as well as opportunities for future technology
development for the Company’s optical imaging and analysis technologies. Dr.
Darrell Rigel, Clinical Professor of Dermatology at New York University
Medical Center, will moderate the meeting and Dr. Monica Scheel of Kailua
Kona, HI will present her real world experience with MelaFind^® and discuss
its integration into her practice.

The Winter Clinical is expected to have over 400 dermatologists in attendance.
Practicing dermatologists will engage in comprehensive updates and dialogue on
the diagnosis and treatment of a variety of medical, surgical and appearance
dermatology conditions led by leading dermatologists from the U.S. and Canada.

MELA Sciences will exhibit four poster presentations focused on the use of
MelaFind^®, its multispectral digital skin lesion analysis tool. The posters
review clinical data from practice and clinical settings, using MelaFind^® in
the assessment of pigmented skin lesions in a variety of patients including
young adults and those with atypical mole syndrome.

According to the Melanoma Research Foundation people under 30 are developing
melanoma at an alarming rate, with the incidence rising by 50% in young women
since 1980. It is the most common form of cancer for young adults aged 25-29
and the second most common cancer in adolescents and young adults aged 15-29.

MelaFind^® is the first and only FDA-approved and CE Mark-approved optical
imaging device for use by dermatologists in the detection and analysis of
melanoma. The Cleveland Clinic recognized it as a Top 10 Medical Innovation
for 2013. Click here for additional information about MelaFind^®.

Please follow us:                
                      Twitter:        @MELASciencesIR or @MelaFind
                      StockTwits:     @MELASciencesIR
                      Facebook:       www.facebook.com/MelaFind

About MELA Sciences, Inc. www.melasciences.com

MELA Sciences is a medical device company developing dermatology diagnostics
utilizing state-of-the-art optical imaging. The flagship product is
MelaFind^®, an FDA, PMA and CE Mark approved, non-invasive diagnostic tool to
aid dermatologists in melanoma evaluation and diagnosis. MelaFind^® uses a
variety of visible to near-infrared light waves to evaluate skin lesions from
the surface to 2.5 mm beneath the skin. It provides images and data on the
relative disorganization of a lesion's cell structure that provides
substantial additional perspective to aid melanoma diagnosis. MELA is also
exploring new potential uses for its core imaging technology and algorithms.

Contact:

Media
MELA Sciences, Inc.
Diana Garcia Redruello, 212-518-4226
dgarcia@melasciences.com
or
Investors
Catalyst Global
Toni Trigiani, David Collins, 212-924-9800
mela@catalyst-ir.com
 
Press spacebar to pause and continue. Press esc to stop.